Study of Visual Function and Vision-Related Quality of Life Before and After Vitreous Injection of Faricimab in Retinal Vein Occlusion

Study of Visual Function and Vision-Related Quality of Life Before and After Vitreous Injection of Faricimab in Retinal Vein Occlusion - Study of Visual Function and Vision-Related QOL Before and After Vitreous Injection of Faricimab in RVO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057118

Enrollment

Registered

2025-02-26

Start date

2025-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Vein Occlusion

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who attended the Department of Ophthalmology of Nippon Medical School Hospital with BRVO or CRVO (central retinal thickness of 250 um or more) and are scheduled to receive farisimab injection treatment, and who have obtained consent for this study using the consent explanation document.

Exclusion criteria

Exclusion criteria: Patients with RVO in both eyes Patients treated for the following CME within 90 days (steroid therapy, anti-VEGF injection, carbonic anhydrase inhibitor eye drops) Patients undergoing endophthalmic surgery within 90 days Patients undergoing intraocular photocoagulation within 30 days Patients who have undergone vitrectomy. Patients with moderate or severe cataract or refractive error that may affect visual function (Grade 3 or higher on the Emery-Little classification, etc.) Patients with other ocular diseases Patients with hypertensive or hyperglycemic emergencies Patients who are judged to be inappropriate as research subjects by the principal investigator.

Design outcomes

Primary

Measure	Time frame
visual function (contrast sensitivity)	—

Secondary

Measure	Time frame
visual function (visual acuity,metamorphopsia, aniseikonia, stereopsis), number of injections, inter-injection period(number of recurrences, duration), vision-related quality of life, patient satisfaction	—

Countries

Japan

Contacts

Public ContactNaka Shiratori

Nippon Medical School Hospital Ophthalmology

shiratori@nms.ac.jp03-3822-2131

Outcome results